Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot consistency and safety of IMVAMUNE smallpox vaccine
NCT01144637Phase 3Completed
- Sponsor
- Bavarian Nordic
- Start
- Feb 2013
- Primary completion
- Nov 2013
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of JYNNEOS in smallpox (4 arms), sponsored by Bavarian Nordic. Primary endpoint: Plaque Reduction Neutralization Test Geometric Mean Titers. Started Feb 2013; status: completed.
02
Drugs
JYNNEOS
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT01144637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01144637.